Arcutis Biotherapeutics, Inc (ARQT)

Etorro trading 970x250
Arcutis Biotherapeutics, Inc (ARQT) Logo

About Arcutis Biotherapeutics, Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California. Address: 3027 Townsgate Road, Westlake Village, CA, United States, 91361

Arcutis Biotherapeutics, Inc News and around…

Latest news about Arcutis Biotherapeutics, Inc (ARQT) common stock and company :

MDU Resources and AppHarvest Stock See Action From Activist Investors
12 Aug, 2022 Yahoo! Finance

Activists file with the SEC on MDU Resources Group, Argo Group International, Arcutis Biotherapeutics, AppHarvest, and MP Materials

Can Arcutis Biotherapeutics, Inc. (ARQT) Climb 123% to Reach the Level Wall Street Analysts Expect?
10 Aug, 2022 Yahoo! Finance

The mean of analysts' price targets for Arcutis Biotherapeutics, Inc. (ARQT) points to a 122.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older
10 Aug, 2022 Yahoo! Finance

Next-generation topical PDE4 inhibitor for adults and adolescents with plaque psoriasis now available in pharmacies nationwideEffective, safe, and very well-tolerated steroid-free cream that rapidly clear plaques and reduces itch Arcutis committed to ensuring affordable access through responsible pricing, Arcutis Cares™ and ZORYVE Direct™ patient access support program WESTLAKE VILLAGE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-st

What Kind Of Shareholders Own Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)?
08 Aug, 2022 Yahoo! Finance

The big shareholder groups in Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) have power over the company. Institutions...

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
04 Aug, 2022 FinancialContent

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in ...

Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update
04 Aug, 2022 Yahoo! Finance

Received U.S. Food and Drug Administration (FDA) approval for ZORYVE™ (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis, in individuals 12 years of age and olderAnnounced positive topline results from pivotal Phase 3 trial of roflumilast foam in seborrheic dermatitis, with anticipated New Drug Application (NDA) submission in the first quarter of 2023Completed enrollment in INTEGUMENT-1, the first of two pivotal Phase 3 trials in subjects with atop

Arcutis Biothera Stock Joins Rank Of Stocks With RS Ratings Over 90
04 Aug, 2022 FinancialContent

Arcutis Biothera shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis
04 Aug, 2022 Yahoo! Finance

A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trialEnrollment continues in INTEGUMENT-2 with topline data from both trials expected by end of 2022Atopic dermatitis affects approximately 26 million adults and children in the U.S. WESTLAKE VILLAGE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatolog

This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
04 Aug, 2022 FinancialContent

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average ...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Aug, 2022 Yahoo! Finance

WESTLAKE VILLAGE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 22,200 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 44,500 shares of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee o

Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
03 Aug, 2022 FinancialContent

Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday. Kaspien ...

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
03 Aug, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Alnylam Reports Upbeat Data ...

Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock
03 Aug, 2022 Yahoo! Finance

WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $20.00 per share, representing a premium to the closing price of $19.50 per share on August 2, 2022. In addition, Arcutis has gr

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock
02 Aug, 2022 Yahoo! Finance

WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock. All of the shares in the offering are being sold by Arcutis. The proposed offering is subject to market and other conditions, and there can be no

Analyst Ratings for Arcutis Biotherapeutics
02 Aug, 2022 FinancialContent

Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are ...

Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
02 Aug, 2022 FinancialContent

Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around ...

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
01 Aug, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Arcutis Psoriasis Treatment ...

Arcutis to Host Investor Conference Call Today to Discuss the FDA Approval of ZORYVE™ (roflumilast) Cream 0.3% for Plaque Psoriasis
01 Aug, 2022 Yahoo! Finance

WESTLAKE VILLAGE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, will host a conference call for investors today at 8:30 a.m. EDT to discuss the U.S. Food and Drug Administration (FDA) approval of ZORYVE (roflumilast) cream 0.3% for treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. Dial

Recap Of Friday's Biotech Catalysts - End of The Day Summary
29 Jul, 2022 FinancialContent

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ...

Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
29 Jul, 2022 FinancialContent

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ...

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
29 Jul, 2022 Yahoo! Finance

First and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis Approved for once-daily treatment in mild, moderate, and severe plaque psoriasis with no limitations on duration of useEstablished efficacy – provides rapid clearance of plaques and reduction of itch in all affected areas of the body Safe and very well-tolerated, steroid-free cream with minimal application site reactionsCommercial product expected to be available by mid-August

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
29 Jul, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Bausch Health To Appeal ...

7 Biotech Stocks to Buy for Q3
18 Jul, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. The post 7 Biotech Stocks to Buy for Q3 appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

Arcutis Biotherapeutics Reaches Regulatory Milestone with Health Canada Acceptance of New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
11 Jul, 2022 Yahoo! Finance

Arcutis Canada Inc., a medical dermatology company and subsidiary of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), announced today that Health Canada has accepted the New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) for the treatment of plaque psoriasis in adults and adolescents. The safety and efficacy of roflumilast cream remain under investigation, and market authorization in Canada has not yet been obtained.

Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
11 Jul, 2022 Yahoo! Finance

Submission supported by positive clinical data from the pivotal Phase 3 DERMIS-1 and DERMIS-2 clinical studies, as well as results from long-term safety studiesIf approved, roflumilast cream would be the first and only topical PDE4 inhibitor for psoriasis in Canada Target action date of April 30, 2023 Arcutis is in process of establishing Canadian operations WESTLAKE VILLAGE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), today announced that Health Canad

Mercury Systems and GMS Stock See Action From Activist Investors
01 Jul, 2022 Yahoo! Finance

Starboard Value and Jana Partners reached a deal for seats on defense contractor Mercury Systems’ board. Coliseum Capital lifted its stake in building-products distributor GMS.

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
01 Jul, 2022 FinancialContent

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the ...

Implied SMMV Analyst Target Price: $40
29 Jun, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $40.46 per unit.

Could 2023 Be a Breakout Year for This Pharma Stock?
22 Jun, 2022 FinancialContent

A pending FDA review and promising clinical trial data brings blockbuster potential.

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
06 Jun, 2022 Yahoo! Finance

Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle (P

Arcutis Biotherapeutics, Inc (ARQT) is a NASDAQ Common Stock listed in , ,

970x250